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Abstract
 .To discover a role of glucocorticoid on interleukin-6 IL-6 -induced responses of a macrophage, we investigated the
 .  .effect of IL-6 andror dexamethasone Dex on cellular functions of a mouse macrophage cell line Mm1 cells . The results
 .obtained were as follows. 1 Dex decreased the accumulation of tumor necrosis factor-a induced by IL-6, whereas nitric
oxide production was enhanced by Dex. Moreover, the enhancement of nitric oxide production could be demonstrated to be
 .associated with stimulation of iNOS mRNA expression by the Dex treatment. 2 Cytotoxic activity of Mm1 cells on mouse
 .B16 melanoma cells was much more enhanced by the co-treatment of IL-6 with Dex than IL-6 treatment alone. 3 Dex
 .promoted further the suppression of proliferation induced by IL-6. 4 DNA fragmentation, introduced by the treatment of
cells with IL-6, was further enhanced in the presence of Dex.
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1. Introduction
Glucocorticoids are well known as anti-inflamma-
tory factors, which exhibit anti-inflammatory effects
by stimulating or inhibiting the transcription of a
w xvariety of genes 1 . In macrophages, it has been
reported that glucocorticoid hormones inhibit a vari-
w xety of macrophage functions 2 , especially recog-
nized by the production of inflammatory mediators
 . w xsuch as nitric oxide NO 3 and tumor necrosis
 . w xfactor-a TNF-a 4 . However, it is also the fact
that glucocorticoids exert complicated actions from
the view of anti-inflammation. The long-term admin-
istration of glucocorticoids results in serious adverse
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 .effects. In osteoporosis, dexamethasone Dex stimu-
lates the osteoclast-like cell formation from mouse
w xbone marrow culture systems 5 , and the activation
w xof osteoclasts 6 . In rat and human hepatic cells,
glucocorticoids synergize with IL-6 to stimulate the
w xproduction of acute-phase proteins 7,8 .
 .Interleukin-6 IL-6 , originally identified as a B
w xcell differentiation factor 9 , has a variety of biologic
functions. IL-6 acts on myeloma cells as a growth
w xfactor 10 and on hematopoietic stem cells as a
w xmulti-colony stimulating factor 11 . IL-6 induces
cytotoxic T cells from murine thymocytes in the
w xpresence of IL-2 12 . In addition, IL-6 also induces
the differentiation of human B lymphocyte synergisti-
w xcally with glucocorticoids 13 . These diverse func-
tions of IL-6 strongly implicate a role in the regula-
tion of growth and differentiation of many cell types.
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However, many things to be clarified still have been
remained in the function of IL-6, particularly in
relation to Dex action.
 .In a mouse myeloid leukemia cells M1 cells ,
w x w xboth IL-6 14 and Dex 15 act as differentiation
factor. In our previous paper, production of NO in
 .mouse macrophage cell line Mm1 , a subclone of
M1 cells was reported to be markedly induced by
w xIL-6 treatment 16 . In subsequent research of NO
production from Mm1 cells by IL-6 treatment, we
recognized that Dex does not suppress the NO pro-
duction but rather enhances. Moreover, Dex was
suggested to influence on another responses such as
proliferation and cell death induced by IL-6 treat-
ment. In this paper, we investigated about the diverse
function of Dex on IL-6 actions using Mm1 cells.
2. Materials and methods
2.1. Materials
Dulbecco modified MEM culture medium was ob-
 .tained from Nissui Pharmaceutical Tokyo, Japan .
Recombinant human IL-6 was a gift from Dr. K.
Yasukawa Tosoh Niotechnology Research Labora-
.tory, Ayase, Japan . Glucocorticoids and other chem-
ical agents were purchased from Wako Pure Chemi-
 .cals Osaka, Japan . Culture dishes and micro well
plate were obtained from Sumitomo Bakelite Tokyo,
.Japan .
2.2. Cell lines and culture
M1 cell line was isolated from myeloid leukemic
w xcells of an SL strain mouse 17 . Mm1 subclone was
w xisolated from M1 and characterized in 1973 18 .
Mm1 cells were cultured in MEM culture medium
containing 5% horse serum and two-fold concentra-
tion of amino acids plus vitamins.
2.3. Measurement of nitrite concentration for assess-
ment of NO production
Nitrite concentration in the culture supernatant was
measured by Griess reaction. Culture supernatant 50
.ml was mixed with 75 ml of 0.2 M acetate buffer
and 75 ml of Griess reagent containing 0.05%
naphthyl-ethylene diamine, 0.5% sulfanilamide and
.2.5% phosphorous acid . Absorbance was measured
at 540 nm after incubated for 20 min at room temper-
ature. Nitrite concentration was determined from a
standard curve by using 0–60 nmolrml of sodium
nitrite dissolved in 5% HS-MEM.
2.4. RT-PCR analysis of NO synthase mRNA expres-
sion
w xTotal RNA was prepared by AGPC method 19 .
The final preparation was quantitated spectrophoto-
metrically and then incubated with reverse transcrip-
tase at 37 for 30 min. RT-PCR method was carried
out according to the method described by Svetic et al.
w x20 . Oligonucleotide primers for NO synthase were
synthesized based on the sequences described by
w x  XLyons et al. 21 . These primers 5 -primer: ACC-
TACTTCCTGGACATTACGACCC; 3X-primer:
.AAGGGAGCAATGCCCGTACCAGGCC gener-
ated a 456 bp band. Oligonucleotide primers for
 Xb-actin 5 -primer: GTGGGCCGCTCTAGGCAC-
CAA; 3X-primer: CTCTTTGATGTCACGCAC-
.GATTTC were used as control. These primers gen-
erated a 540 bp band. PCR products were visualized
by electrophoresis through agarose gel containing 1
mgrml of ethidium bromide.
2.5. Assay for TNF acti˝ity
 6 .Mm1 cells 3=10 ceils were seeded in a 35 mm
diameter dish with 100 Urml of IL-6 andror 10y6
M of Dex. In the experiment using Dex, Mm1 cells
were pre-treated for 24 h by 10y6 M of Dex, then the
cell number was counted and seeded with 10y6 M of
 .Dex in the presence or absence of IL-6 100 Urml .
Basal TNF-a activity was determined by the incuba-
 .tion of Mm1 cells for 5 h without stimulants . After
incubation for the indicated times, the supernatants
were collected and transferred to the L929 cells
microplate assay system described as follows.
TNF activity monitored by the cell lytic assay
w xessentially as described by Ruff and Gifford 22 .
Briefly, mouse L929 fibroblastic cells were plated in
96-well plates at 30 000 cellsr0.1 ml to establish a
dense monolayer. After incubation for 5 h at 37 in a
humidified 5% CO atmosphere, 50 ml of actino-2
 .mycin D solution 4 mgrml and 50 ml of test
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samples were added to the wells, and then the cells
were further incubated for 18 h. At the end of the
culture period, the supernatants were removed,
washed twice with phosphate buffered saline, stained
 .with glutaraldehyde 0.25% , and dyed with crystal
 .violet 0.2% in 2% methanol for 10 min. After the
cells were washed with water and allowed to dry, the
cells were solubilized with 1% SDS. The concentra-
tion of the dye was determined by measuring the
absorbance at 546 nm. A dose-response standard
curve was drawn using rMuTNF-a Genzyme: TNF-
.M . The final concentrations of transferred rIL-6,
dexamethasone alone or together did not influenced
on the TNF-a-induced cytolysis of L929 cells in the
presence of actinomycin D.
2.6. Cytotoxicity assay
w xCytotoxicity was assayed by the method 23
counting 51Cr released from labeled target cells as
 5 .follows: Mm1 cells 2=10 cellsrwell were pre-in-
cubated for 24 h with various concentrations of IL-6
 y6 .in the presence or absence of Dex 10 M in a
48-well plate. After pre-incubation, 51Cr-labeled
 5 .mouse B16 melanoma cells 1=10 cellsrwell were
added and then incubated for more 3 days. After
incubation, the radioactivity in the culture supernatant
was counted by gamma-counter. For spontaneous
release, the supernatant of target cells alone was
counted. Moreover, cytolysis of 51Cr-labeled B16
melanoma cells in this assay system was not induced
by treatment of IL-6 andror Dex. The radio activity
in the supernatant of B16 cells treated with IL-6 100
.  y6 .Urml andror Dex 10 M was not changed as
 .compared to the none-treated cells. Cytotoxicity %
w  .was calculated as follows: sample cells cpm sponta-
 .x wneous cpm r total incorporated radioactivity
 .  .x  .cpm spontaneous cpm 100scytotoxicity % . To
 .determine the total incorporated radioactivity cpm ,
51  5 .Cr-labeled B16 melanoma cells 1=10 cells
without treatments of IL-6 andror Dex were lysed
completely with 1% Triton X-100 and the radio
activity was counted.
[ 3 ]2.7. H Thymidine incorporation
 5 .Mm1 cells 1.5=10 cellsrwell were cultured
 .for 2 days with treatment of IL-6 100 Urml in the
 y6 .presence or absence of Dex 10 M in a 48-well
w3 x plate. Then, H thymidine 2 mCi, specific activity
.40–60 Cirmmol was added to each well. After 4 h,
cells were harvested on a glass fiber filter by washing
with saline and 1% trichloroacetic acid and counted
with scintillator by a liquid scintillation counter.
2.8. Culture conditions and DNA extraction for as-
sessment of DNA fragmentation
 7 .Mm1 cells 1=10 cellsrwell were cultured with
 .treatment of IL-6 100 Urml in the presence or
 y6 .absence of Dex 10 M in a 90 mm diameter dish.
After 3 days, cells were harvested by centrifugation
and a portion of cells was utilized for DNA extrac-
tion. Another portion of cells was cultured continu-
ously for three more days with fresh medium in the
absence of inducers.
DNA was extracted according to the method de-
w xscribed by Miller et al. 24 . Extracted DNA samples
were then treated with Rnase for 30 min at 37 and
reprecipitated with ethanol. DNA concentration was
determined by measurement of absorbance at 260
nm. Electrophoresis was performed on a 1.2% agarose
gel at 100 V for 30 min in the presence of 1 mgrml
ethidium bromide. A Hinc II digest of w X174
 . am3cs70 DNA MW Marker 5, Nippon Gene,
.Japan was used as a standard.
2.9. Statistical analysis
The statistical significance of differences between
the groups was determined by applying Student’s
t-test.
3. Results
3.1. Effect of glucocorticoids on NO production in
il-6-induced Mm1 cells
The effect of glucocorticoids on NO production in
 .IL-6-induced Mm1 cells was investigated Table 1 .
These glucocorticoids possessed an enhancing effect
on NO production to a greater or lesser extent. Dex
showed the greatest effect among four glucocorti-
coids. The effect of Dex on NO production of Mm1
 .cells was further investigated in detail Fig. 1 . This
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Table 1
Effect of glucocorticoids on NO production in IL-6-induced Mm1 cells
Treatments of IL-6 andror NO production Relative value
6 .glucocorticoid M  .nmolr10 cells
Control None 4.5 "90.99
 .IL-6 100 Urml None 48.49"3.45 1
y7 ) )Dex 1=10 70.38"0.99 1.45
y5 ) )1=10 68.52"2.73 1.41
y7 )Cortisol 1=10 62.54"3.52 1.29
y5 ) )1=10 71.23"1.28 1.47
y7 )Corticosterone 1=10 64.38"5.77 1.33
y51=10 49.34"2.39 1.02
y7Cortisone 1=10 42.15"3.30 0.87
y51=10 56.00"5.59 1.18
 .Mm1 cells were cultured for 72 h with IL-6 100 Urml in the presence or absence of glucocorticoid. The NO production was then
assayed using respective supernatants as described in Section 2.
The results are presented as means"SD of quadruplicate. Significant difference from IL-6 treatment: ) P-0.01, )) P-0.005.
enhancement was reached to maximum at 10y5–10y7
 y6 .M of Dex. Thus, Dex 10 M was used in the
following experiments. Moreover, it was found that
production of NO was not induced by Dex treatment
alone.
3.2. Effect of Dex on expression of iNOS mRNA in
il-6-induced Mm1 cells
From the above results, iNOS mRNA expression
was deduced to be stimulated by treatment of Dex to
Fig. 1. Effect of Dex on NO- production in IL-6-treated Mm12
 .cells. Mm1 cells were treated for 48 h by IL-6 100 Urml in the
 .  .  y9 y5 .presence v or absence ‘ of Dex 10 –10 M . The
culture supernatants were then assayed for NO- concentration as2
described in Section 2. Results are expressed as means"SD of
four cultures.
IL-6-induced Mm1 cells. Thus, effect of Dex on
expression of iNOS mRNA was examined using IL-
6-induced Mm 1 cells in the presence or absence of
 y6 .  .Dex 10 M for 0–48 h Fig. 2 . By the treatment
of Dex, expression of iNOS mRNA in IL-induced
Mm1 cells was found to be remarkably stimulated
prior to the increment of NO production. From the
finding, the enhancement of NO production by Dex
was demonstrated to be due to stimulation of iNOS
mRNA expression, at least.
Fig. 2. Effect of Dex on iNOS mRNA expression in IL-6-induced
 5 2.Mm1 cells. Mm1 cells 1.5P10 cellsrcm were incubated for
 .  y6 .  .the indicated times without A or with Dex 10 M B in the
 .presence of IL-6 100 Urml . Total RNA of each sample was
reverse transcripted and amplified by using specific primers for
iNOS and b-actin mRNA. PCR products were visualized by
 .electrophoresis. D: Treatment of Dex alone 48 h .
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Fig. 3. TNF-a activities in the supernatants of Mm1 cells. Mm1
 3 .cells 3P10 cellsr35 mm diameter dish were treated by IL-6
 .  .  .  y6100 Urml in the presence v or absence ‘ of Dex 10
.M . At the indicated times, TNF-a activities in the supernatant
was measured as described in Section 2. Values are the means"
SD of four cultures.
3.3. Effect of Dex on TNF-a production in il-6-in-
duced Mm1 cells
A little TNF-a activity without stimulant open
.circles at 0 h was detected in the supernatant of
Mm1 cells during 5 h of the culture period as shown
in Fig. 3. TNF-a activity in the supernatant of IL-6-
treated Mm1 cells showed a maximum increase at 1 h
after culture, and then gradually restored to control
level for 4 h. Such an increment of TNF-a induced
by IL-6-treatment was significantly suppressed by
Dex as shown in Fig. 3. Moreover, the effect of IL-6
andror Dex on TNF-a-induced cytolysis in actino-
mycin D-treated L929 cells was examined with vari-
ous concentrations of TNF-a by incubations of IL-
Fig. 4. Effect of Dex on IL-6-induced cytotoxic activity in Mm1
 5 .cells. Mm1 cells 2P10 cellsrwell were pre-incubated for 24 h
 .by various concentrations of IL-6 in the presence v or absence
 .  y6 . 51‘ of Dex 10 M . After the incubation, Cr-labeled mouse
 5 .B16 melanoma cells 1P10 cellsrwell were added to the incu-
bation mixture and then furthermore incubated. The cytotoxicity
was calculated as described in Section 2. Results are expressed as
means"SD of four cultures.
6-treated Mm1 cells, which were cultured in the
presence or absence of Dex. However, the TNF-a-in-
duced cytolysis was not changed by the treatments of
 .IL-6 andror Dex not shown data .
3.4. Effect of Dex on cytotoxic acti˝ity of Mm1 cells
˝ersus tumor cells
The cytotoxicity of Mm1 cells versus tumor cells
was examined using mouse B16 melanoma cells as
shown in Fig. 4. Mm1 cells acquired dose-depen-
dently the cytotoxic activity by the treatment of IL-6.
Table 2
w3 xEffect of IL-6 andror Dex on H thymidine in incorporation in Mm1 cells
3w x  .Treatment H TdR incorporation dpmrculture Relative value
Control 521 547"43 318 1
y6 ) .Dex 1P10 M 378 337"40 724 0.73
) .IL-6 100 Urml 194 314"31 888 0.37
y6 ) .  .IL-6 100 Urml Dex 1P10 M 15 772"3339 0.03
w3 x  .Mm1 cells were cultured for 48 h with IL-6 andror Dex. H Thymidine TdR incorporation during the final 4 h in culture was
measured as described in Section 2.
The results are expressed as mean"SD of quadruplicate.
) Significant difference from control: P-0.005.
( )M. Kanematsu, Y. SuketarBiochimica et Biophysica Acta 1357 1997 192–200 197
Fig. 5. Changes in cell number after the challenge of rIL-6
andror Dex treatment. Mm1 cells were incubated in 60 mm
6  . y6diameter dish at 1.5=10 cells with medium alone I , 10 M
 .  .  .of Dex ^ , 100 Urml of rIL-6 ‘ , or with both v Dex
 y6 .  .10 M and rIL-6 100 Urml . After incubation for the
indicated times, cells were harvested and counted. Results are
expressed as means"SD of four measurements.
B16 melanoma cells were introduced to lysis of more
than 90% by the co-culture with the IL-6 50
.Urml -treated Mm1 cells. Moreover, the cytotoxic
activity of IL-6- treated Mm1 cells was markedly
stimulated by Dex; nearly 90% of B16 cells were
lyzed by co-culture of the Mm1 cells, which were
 .treated with a smaller amount 10 Urml of IL-6 in
 y6 .the presence of Dex 10 M .
3.5. Effect of Dex on proliferation of Mm1 cells
The effect of Dex on proliferation of Mm1 cells
w3 xwas examined by the measurement of H thymidine
 .incorporation at day 2 Table 2 and by the changes
 . w3 xof cell number Fig. 5 . The H thymidine incorpora-
tion was suppressed by the challenge of IL-6 treat-
ment, but a portion of cells still proliferated. Co-treat-
w3 xment of Dex with IL-6 suppressed the H thymidine
incorporation almost completely. These results were
consisted with the changes of cell number.
w3 xH Thymidine incorporation was slightly suppressed
by the treatment of Dex alone. The suppression might
be due to decrease of the cell numbers as compared
to control.
3.6. Effect of Dex on the induction of apoptotic cell
death
The molecular alterations of DNA under the vari-
ous conditions after treatments of 10y6 M Dex
andror 100 Urml of IL-6 are shown in Fig. 6. At the
ends of 3 days culture, DNA fragmentation pro-
ceeded slightly in cells treated with Dex alone. This
fragmentation might be induced by apoptosis within
first day so that the number of Dex-treated cells was
 .scarcely increased from 0 to 1 day Fig. 6 . IL-6 was
suppressive to this Dex-induced DNA fragmentation.
On the other hand, IL-6-treated Mm1 cells were
undergoing DNA fragmentation when cultured subse-
Fig. 6. Effect of Dex on the induction of DNA fragmentation in
IL-6-induced Mm1 cells. DNA was extracted from Mm1 cells as
described in Section 2, and 2 mg DNA was run on agarose gels.
A standard 79 to 1,057-bp DNA is shown in lane 1. Lane 2
corresponds to DNA extracted from non activated Mm1 cells.
Other lanes correspond to DNA harvested from Mm1 cells at the
 y6 .ends of cell culture in the presence or absence of Dex 10 M
 .  .  .andror IL-6 100 Urml . Dex lane 3 , IL-6 lane 4 and
 .  .DexqIL-6 lane 5 were cultured for 3 days 0–3 day in the
 .  .presence of their stimulants. Dex lane 6 , IL-6 lane 7 and
 .DexqIL-6 lane 8 were cultured for 3 days in the same condi-
 .tions and then furthermore incubated for 3 days 4–6 day after
removals of the stimulants.
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quently after the withdrawal of IL-6. This DNA
fragmentation was more remarkable in the Mm1 cells
which were treated with IL-6 in the presence of Dex.
4. Discussion
In this study, we first examined the effect of
glucocorticoids on NO production. Dex and the other
glucocorticoids were found to enhance the NO pro-
duction induced by IL-6 treatment. Moreover, iNOS
mRNA expression in IL-6-induced Mm1 cells was
demonstrated to be stimulated prior to the enhance-
ment of the NO production by Dex treatment. The
reports so far have been described that the effect of
w xDex on NO production is only suppressive 25 .
Nonetheless, it was also confirmed by another
macrophage cell line that Dex preferably enhanced
the NO production induced by IFN-g manuscript in
.preparation . From their evidence, effect of Dex on
NO production may vary by the cell types.
On the other hand, it has not been clarified how
can Dex affect the expression of iNOS mRNA. The
promoterrenhancer region of murine iNOS gene has
been cloned, and the elements that several transcrip-
w xtional factor can bind have been identified 26,27 .
However, the iNOS promoterrenhancer region lacked
the steroid response elements. An element that activa-
w xtor protein-1 can bind existed in this region 26,27 ,
and it was reported that glucocorticoid receptor asso-
ciates with activator protein-1 directly to regulate the
w xtranscriptional control 28 . However, the regulation
system is now questioned in terms of direct associa-
tion.
As NO has been demonstrated to be a mediator of
inflammation, the enhancement of NO production by
Dex may be inconsistent with the fact. Nonetheless, a
dramatic increase in hepatic damage by blocking the
NO production has been demonstrated in inflamma-
w xtion-inducing mice model 29 . This result suggests
that NO is capable of exhibiting the anti-inflamma-
tory action under the specific circumstance. Further-
more, it is noteworthy that hepatocytes produce
acute-phase proteins in response to IL-6, and Dex
synergistically enhances the proteins through the in-
w xteraction of IL-6-response elements 7,8 .
Dex which lowered the concentrations of IL-6 to
obtain the same degree of cytolytic activity, may be
due to the enhancement of NO production. Thus,
there was no effect of TNF-a production on this
assay, so that B16 melanoma cells were co-cultured
with Mm1 cells pre-treated by IL-6 andror Dex for
24 h. TNF-a has been reported to have an enhancing
w xeffect of NO production 30 . Indeed, TNF response
element exists in the promoterrenhancer region on
w xiNOS gens 26,27 . However, endogenous TNF-a did
not influence on the NO production in IL-6-treated
Mm1 cells, because only high concentrations of re-
combinant TNF-a was rather suppressive for the NO
production and the neutralizing antibody for TNF-a
 .had no effect data not shown .
On the other hand, the endogenous NO and TNF-a
might be able to influence on the change of prolifera-
tive ability and the induction of cell death. As for the
influence of NO on the proliferation, our laboratory
had reported that endogenous NO participated in the
blocking the cell cycle of IL-6-induced Mm1 cells in
w xthe early G qM phase 31 . It is expected that this2
tendency is more emphasized under the condition of
increased NO production by Dex co-treatment, On
the other hand, TNF-a do not influence on the
w xproliferation of Mm1 cells 32 .
Some reports insist on the correlation of produced
w xNO with apoptosis in activated macrophages 33,34 .
In view of the mechanism of apoptosis induced by
NO, it might be mediated by the inhibition of mito-
w xchondrial Fe-S containing enzymes 35 , since the
inhibitor of mitochondrial electron flow was shown
w xto be able to induce apoptosis 36 . In addition,
structural damage of mitochondria parallel to NO
w xproduction in host cells had been recognized 37 . A
portion of our results supports this notion, because
the degree of DNA fragmentation subsequent to the
activation was more proceeded in relation to the
enhancement of NO production by the co-treatment
of Dex with IL-6. However, these mechanism, namely
the trigger of DNA fragmentation by NO, will not
account for that of Mm1 cells entirely. Since these
signal should be transmitted soon and DNA fragmen-
tation should be resulted in a relatively short time,
whereas DNA fragmentation in Mm1 cells induced
by IL-6 withrwithout Dex gradually progressed after
the removal of stimulus when the series of NO
production had been completed. Moreover, Dex alone
treatment induced the DNA fragmentation to some
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extent in a relatively early stage despite the no NO
production.
As for the Dex-induced apoptosis, it has been
shown that Dex induces thymocyte apoptosis accom-
panied with DNA fragmentation caused by the activa-
w xtion of calcium-dependent endonuclease 38,39 . So
the DNA fragmentation induced by Dex alone treat-
ment in Mm1 cells might be introduced by the same
mechanism as above. It is notable that IL-6 was
inhibiting to this Dex action.
In contrast, the DNA fragmentation induced by
IL-6 treatment was resemble to the activation-in-
duced apoptosis that is introduced in the terminal
differentiated macrophages as Munn and co-workers
w x40 demonstrated. Dex might proceeded this pro-
grammed cell death by acting as an enhancer of
differentiation and activation in association with IL-6.
This system can be evaluated as anti-inflammatory
effect of Dex; it may cause the serious situation for
host body if activated-macrophages remain at the site
of inflammation.
In this study, we demonstrated that glucocorticoids
are an important role for IL-6-induced cellular func-
tions in Mm1 cells using Dex.
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